✦ LIBER ✦

S-HAM induction chemotherapy with or without GM-CSF in patients with high-risk myelodysplastic syndromes

✍ Scribed by W. Verbeek; B. Wörmann; P. Koch; C. Aul; H. Hinrichs; L. Balleisen; J. M. Rowe; J. Bennett; T. Büchner; W. Hiddemann

Book ID: 105990250
Publisher: Springer
Year: 1997
Tongue: English
Weight: 173 KB
Volume: 74
Category: Article
ISSN: 0939-5555
DOI: 10.1007/s002770050285

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prognostic relevance of achieving cytoge

Prognostic relevance of achieving cytogenetic remission in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome following induction chemotherapy

✍ Sebastian Balleisen; Andrea Kuendgen; Barbara Hildebrandt; Rainer Haas; Ulrich G 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 249 KB

Cytogenetic findings at diagnosis have influence on prognosis in patients with acute myelogenous leukaemia (AML) or MDS who undergo induction chemotherapy. Assessment of remission and treatment decisions are based on cytological findings. We analyzed the prognostic impact of cytogenetic remission st

Maintenance treatment with azacytidine f

Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy

✍ Michael Grövdal; Mohsen Karimi; Rasheed Khan; Anni Aggerholm; Petar Antunovic; J 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 498 KB

Acute pulmonary failure during remission

Acute pulmonary failure during remission induction chemotherapy in adults with acute myeloid leukemia or high-risk myelodysplastic syndrome

✍ Ali Al Ameri; Charles Koller; Hagop Kantarjian; Farhad Ravandi; Srdan Verstovsek 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 142 KB 👁 2 views

Intensive chemotherapy with idarubicin,

Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia

✍ W. K. Hofmann; G. Heil; C. Zander; S. Wiebe; O. G. Ottmann; L. Bergmann; K. Hoef 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 109 KB

Phase II study of combination human reco

Phase II study of combination human recombinant GM-CSF with intermediate-dose cytarabine and mitoxantrone chemotherapy in patients with high-risk myelodysplastic syndromes (RAEB, RAEBT, and CMML): An Eastern Cooperative Oncology Group Study

✍ John M. Bennett; Mary S. Young; Jane L. Liesveld; Elisabeth Paietta; Kenneth B. 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 39 KB 👁 2 views

Risk of secondary myeloid leukemia and m

Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies

✍ C. Kollmannsberger; J. T. Hartmann; L. Kanz; C. Bokemeyer 📂 Article 📅 1998 🏛 Springer-Verlag 🌐 English ⚖ 296 KB